Intra-Cellular Therapies, Inc. (ITCI) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Intra-Cellular Therapies, Inc. (ITCI) Bundle
Whether you’re an investor or analyst, this ITCI DCF Calculator is your go-to resource for accurate valuation. Preloaded with Intra-Cellular Therapies, Inc. real data, you can adjust forecasts and observe the effects in real-time.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .1 | 22.5 | 81.7 | 249.1 | 464.4 | 912.9 | 1,794.8 | 3,528.6 | 6,937.3 | 13,638.6 |
| Revenue Growth, % | 0 | 37071.49 | 262.65 | 204.91 | 86.4 | 96.6 | 96.6 | 96.6 | 96.6 | 96.6 |
| EBITDA | -153.5 | -230.7 | -285.2 | -263.0 | -158.9 | -792.8 | -1,558.7 | -3,064.3 | -6,024.4 | -11,843.9 |
| EBITDA, % | -253303.3 | -1023.93 | -348.99 | -105.55 | -34.21 | -86.84 | -86.84 | -86.84 | -86.84 | -86.84 |
| Depreciation | .5 | .5 | .5 | .7 | .5 | 188.7 | 371.1 | 729.5 | 1,434.3 | 2,819.7 |
| Depreciation, % | 787.16 | 2.34 | 0.65276 | 0.26331 | 0.1137 | 20.67 | 20.67 | 20.67 | 20.67 | 20.67 |
| EBIT | -154.0 | -231.2 | -285.7 | -263.6 | -159.4 | -793.0 | -1,559.1 | -3,065.1 | -6,026.0 | -11,847.0 |
| EBIT, % | -254090.46 | -1026.28 | -349.65 | -105.82 | -34.32 | -86.86 | -86.86 | -86.86 | -86.86 | -86.86 |
| Total Cash | 224.0 | 657.4 | 412.3 | 591.9 | 497.9 | 912.9 | 1,794.8 | 3,528.6 | 6,937.3 | 13,638.6 |
| Total Cash, percent | .4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 10.8 | 20.2 | 75.2 | 114.0 | 232.2 | 456.5 | 897.5 | 1,764.6 | 3,469.1 |
| Account Receivables, % | 0 | 47.78 | 24.67 | 30.18 | 24.55 | 25.44 | 25.44 | 25.44 | 25.44 | 25.44 |
| Inventories | .0 | 7.1 | 7.9 | 23.9 | 11.6 | 97.1 | 190.8 | 375.1 | 737.5 | 1,449.9 |
| Inventories, % | 0 | 31.32 | 9.73 | 9.6 | 2.51 | 10.63 | 10.63 | 10.63 | 10.63 | 10.63 |
| Accounts Payable | 7.4 | 5.5 | 8.7 | 10.4 | 11.5 | 258.7 | 508.6 | 1,000.0 | 1,965.9 | 3,865.0 |
| Accounts Payable, % | 12249.89 | 24.42 | 10.64 | 4.17 | 2.47 | 28.34 | 28.34 | 28.34 | 28.34 | 28.34 |
| Capital Expenditure | -.7 | -.3 | -.3 | -.8 | -.3 | -186.2 | -366.0 | -719.5 | -1,414.5 | -2,781.0 |
| Capital Expenditure, % | -1155.52 | -1.18 | -0.39866 | -0.31228 | -0.05792795 | -20.39 | -20.39 | -20.39 | -20.39 | -20.39 |
| Tax Rate, % | -0.45743 | -0.45743 | -0.45743 | -0.45743 | -0.45743 | -0.45743 | -0.45743 | -0.45743 | -0.45743 | -0.45743 |
| EBITAT | -154.0 | -231.2 | -285.7 | -263.6 | -160.1 | -793.0 | -1,559.1 | -3,065.1 | -6,026.0 | -11,847.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -146.8 | -250.7 | -292.6 | -333.1 | -185.4 | -746.8 | -1,622.1 | -3,189.1 | -6,269.7 | -12,326.2 |
| WACC, % | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -16,945.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -12,573 | |||||||||
| Terminal Value | -178,767 | |||||||||
| Present Terminal Value | -116,010 | |||||||||
| Enterprise Value | -132,955 | |||||||||
| Net Debt | -131 | |||||||||
| Equity Value | -132,824 | |||||||||
| Diluted Shares Outstanding, MM | 96 | |||||||||
| Equity Value Per Share | -1,385.29 |
What You Will Get
- Real ITCI Financials: Access to historical and projected data for precise valuation.
- Adjustable Inputs: Tailor WACC, tax rates, revenue growth, and capital expenditures to your needs.
- Automatic Calculations: Dynamic computation of intrinsic value and NPV.
- Scenario Analysis: Evaluate various scenarios to assess Intra-Cellular Therapies' future performance.
- Clear and Intuitive Design: Designed for professionals while remaining user-friendly for newcomers.
Key Features
- 🔍 Real-Life ITCI Financials: Pre-filled historical and projected data for Intra-Cellular Therapies, Inc. (ITCI).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Intra-Cellular Therapies’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Intra-Cellular Therapies’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for Intra-Cellular Therapies, Inc. (ITCI).
- Step 2: Review the pre-filled financial data and forecasts for Intra-Cellular Therapies.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the findings for your investment strategies.
Why Choose This Calculator for Intra-Cellular Therapies, Inc. (ITCI)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters to suit your specific analysis needs.
- Real-Time Valuation: Witness immediate updates to Intra-Cellular Therapies’ valuation as you tweak inputs.
- Preloaded Data: Comes with Intra-Cellular Therapies’ actual financial metrics for swift evaluations.
- Endorsed by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for assessing Intra-Cellular Therapies, Inc. (ITCI) stock.
- Pharmaceutical Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Intra-Cellular Therapies, Inc. (ITCI).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling related to the biotech sector.
- Biotech Enthusiasts: Gain insights into how companies like Intra-Cellular Therapies, Inc. (ITCI) are valued in the healthcare market.
What the Template Contains
- Historical Data: Includes Intra-Cellular Therapies, Inc.'s (ITCI) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Intra-Cellular Therapies, Inc.'s (ITCI) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Intra-Cellular Therapies, Inc.'s (ITCI) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.